A new PRO-based evaluation (PROBE) can be used to facilitate clinical care, clinical and epidemiological research, and quality improvement among patients with inflammatory bowel disease (IBD), a new study suggests. Using the Crohn’s & Colitis Foundation’s IBD Partners cohort, researchers performed several cross-sectional and longitudinal analyses to create a new PROBE of quality of life (QoL) among patients with Crohn’s disease (CD) and ulcerative colitis (UC). They found:
- A total of 4,854 patients (64% CD, 36% UC) completed surveys with 6 items included in the final PROBE.
- Compared with baseline there was a significant decrease in PROBE scores at follow-up among patients who experienced a flare for UC and CD.
- Among those with stable disease activity, Cronbach alpha was 0.87 in CD and 0.82 in UC.
Barnes EL, Kappelman MD, Long MD, Evon D, Martin CF, Sandler RS. A novel patient-reported outcome-based evaluation (PROBE) of quality of life in patients with inflammatory bowel disease. [Published online ahead of print March 1, 2019]. Am J Gastroenterol. doi:10.14309/ajg.0000000000000177.